RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:251589

Astrocytoma grade 3

high confidenceDisorder

Also known as: Anaplastic astrocytoma

Publications

14,811

96.3th percentile

Trials

190

Interventional, condition-specific

Researchers

1,367

Distinct authors in sample

Gene link

BRAF

Limited

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, high-grade, malignant glial tumor, histologically characterized by abundance of pleomorphic astrocytes and multiple mitotic figures, often associated with diffuse infiltration of the surrounding tissue, considerable edema and mass effect and involvement of the contralateral brain. Depending on the primary localization of the tumor, patients can present with signs of raised intracranial pressure (headache, vomiting, papilledema), , neurological deficits, and/or behavioral changes. The tumor is most commonly localized in the frontal and temporal lobes, brain stem and spinal cord.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

anaplastic astrocytoma · astrocytoma, anaplastic, malignant · grade III astrocytic neoplasm · grade III astrocytic tumor · grade III astrocytic tumour · grade III astrocytoma · malignant astrocytoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Limited — BRAF

  2. LiteraturePresent

    14,811 matched papers (7,643 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    190 matched on ClinicalTrials.gov (15 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Possibly — only limited evidence so far for BRAF.

GenCC classification: Limited.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

63

Drugs / clinical candidates · MONDO_0016684

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

14,811

14,811 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

14,811 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

7,643 in the last 10 years · high confidence · 96.3th percentile (publications denominator)

Phrase hits: 14,811 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,367

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang Y6 papers · 2026

    Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

    Papers in Europe PMC
  2. 02
    Li J5 papers · 2026

    Department of Stomatology, The First Affiliated Hospital of Hunan Traditional Chinese Medical College (Hunan Provincial Directly Affiliated Hospital of Traditional Chinese Medicine), Zhuzhou, China.

    Papers in Europe PMC
  3. 03
    Jakubowicz-Gil J4 papers · 2025

    Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.

    Papers in Europe PMC
  4. 04
    Liu Y4 papers · 2025

    Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

    Papers in Europe PMC
  5. 05
    Rzeski W4 papers · 2025

    Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.

    Papers in Europe PMC
  6. 06
    Chen Z3 papers · 2025

    Division of Stem Cell Biology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, 060-0815, Japan.

    Papers in Europe PMC
  7. 07
    Lu X3 papers · 2024
    Papers in Europe PMC
  8. 08
    Maciejczyk A3 papers · 2025

    Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.

    Papers in Europe PMC
  9. 09
    Sumorek-Wiadro J3 papers · 2025

    Department of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland. joanna.sumorek-wiadro@mail.umcs.pl.

    Papers in Europe PMC
  10. 10
    Wang F3 papers · 2026

    Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

190

interventional trials for this specific condition

190 interventional trials matched this specific condition name; 15 currently recruiting in our sample.

Data as of 11 September 2026

190 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.2th percentile).

high confidence · 99.2th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

190 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

17 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 66 · after dedupe 66 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 66 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (66)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Astrocytoma grade 3 — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Astrocytoma grade 3" OR "Anaplastic astrocytoma" OR "astrocytoma, anaplastic, malignant" OR "grade III astrocytic neoplasm" OR "grade III astrocytic tumor" OR "grade III astrocytic tumour" OR "grade III astrocytoma" OR "malignant astrocytoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Astrocytoma grade 3" OR "Anaplastic astrocytoma" OR "astrocytoma, anaplastic, malignant" OR "grade III astrocytic neoplasm" OR "grade III astrocytic tumor" OR "grade III astrocytic tumour" OR "grade III astrocytoma" OR "malignant astrocytoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 190 interventional · 17 observational · 1 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T10:48:19.794Z